Episode 164 - November 21, 2025

What It Covers

Biotech insiders analyze the heated M&A environment with competitive bidding wars for Avadel and record-breaking acquisitions including J&J's $3 billion Halda deal and Merck's Sadara purchase. Discussion covers FDA functionality concerns, vaccine policy changes at CDC, drug pricing strategies from Arrowhead and Novo Nordisk, and emerging royalty-based business models in biotech.

Key Questions Answered

• •Competitive M&A Dynamics: Alkermes secured Avadel for $22.50 per share ($21 cash plus $1.50 CVR) after outbidding Lundbeck in a rare public auction for the narcolepsy drug Lumryz, which generates $240-260 million annually with 50% year-over-year growth. The deal represents 10x current sales but only 3.5-5x projected peak sales of $500-750 million, making it immediately accretive and demonstrating pharma's willingness to pay premiums for growth assets.
• •Phase One Acquisition Record: J&J paid approximately $3 billion for Halda Therapeutics, the largest ever phase one company acquisition, securing HLD-0915, an oral small molecule for prostate cancer with hold-and-kill mechanism. This surpasses the previous record of $2.75 billion for Fellow to Spio and exceeds the $1 billion J&J paid for phase three Zytiga in 2009, reflecting both higher drug pricing potential and strategic value of platform technologies.
• •FDA Operational Challenges: November 2025 survey reveals 82% of biotech companies worry about FDA functionality, reporting inability to secure meetings, receiving written-only responses, reviewers lacking therapeutic area expertise, complete team turnovers, and inadequate package reviews. These issues create uncertainty for phase two trial designs that could impact registrational trials years later, particularly affecting programs without clear precedent or straightforward development paths.
• •Strategic Pricing Approaches: Arrowhead priced its FCS drug at $60,000 annually, a 90% discount to Ionis's $595,000 ultra-orphan price, positioning for the broader severe hypertriglyceridemia market where Ionis plans $15-20,000 pricing. This strategy reflects different clinical trial designs targeting higher-risk versus broader populations, potentially creating differentiated contracting approaches with payers despite similar efficacy profiles and eventual label overlap.
• •GLP-1 Price Competition: Novo Nordisk reduced Wegovy pricing to $200 monthly for starting doses through Q1 2026, then $350 monthly versus previous $500, matching Trump RX pricing to compete for new patient starts. The multidose pen drops to $299 monthly while oral GLP-1s start at $150 monthly. Despite aggressive discounting, analysts maintain peak sales projections above $5 billion, expecting volume increases to compensate for lower prices.
• •Royalty Business Model Shift: Zymeworks announced transition to diversified royalty-based model following positive HER2 bispecific data with Jazz, implementing $125 million buyback while partnering internal pipeline to reduce single-program risk. The strategy involves monetizing future milestones and royalties, in-licensing undervalued compounds, acquiring platforms for royalty generation, and purchasing undervalued royalty streams, representing shareholder-friendly capital redeployment versus traditional high-risk development models.